🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Stage II Squamous Cell Carcinoma of the Head and Neck

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC NCT05941338Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Tirelizumab ,+Carboplatin+albumin-bound paclitaxel Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) NCT04807140Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Toripalimab, nab-paclitaxel, carboplatin, Toripalimab, Surgical resection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) NCT07485296Phase 21 site📍 Rozzano Gruppo Oncologico del Nord-Ovest · Tests: Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., place… AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy NCT06494995Phase 21 site📍 Shanghai Fudan University · Tests: Cadonilimab, Low-dose radiotherapy, SBRT, Capecitabine Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC NCT06876844Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: combination of Surufatinib and Envolizumab Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893NA2 sites📍 San Francisco📍 Walnut Creek University of California, San Francisco · Tests: Radiation Therapy (RT) Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Pembrolizumab, Cisplatin, Paclitaxel-albumin Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma NCT07254585Phase 21 site📍 Shanghai CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6010 injection, Enlonstobart injection, Pembrolizumab injection Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607Phase 298 sites📍 Los Angeles📍 Baltimore📍 New York AstraZeneca · Tests: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites📍 Scottsdale📍 Fullerton📍 Los Angeles Alentis Therapeutics AG · Tests: ALE.P02, Pembrolizumab Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma NCT07665190Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Becotatug Vedotin and Pucotenlimab Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） NCT06509568Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin (Or Carboplatin), Radical surg… PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY NCT06354140Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Tegafur Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N NCT06640725Phase 21 site📍 Vandœuvre-lès-Nancy Groupe Oncologie Radiotherapie Tete et Cou · Tests: Avelumab administration at 10mg/kg, Cetuximab (Erbitux) A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06857279Phase 22 sites📍 Jinan📍 Shanghai Shanghai Henlius Biotech · Tests: HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3, HLX43 DOSE 2 + HLX10, HLX43 DOSE 3 + HLX10 Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC NCT06052839Phase 21 site📍 Pittsburgh Dan Zandberg · Tests: Pembrolizumab, Carboplatin, Paclitaxel Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma NCT04220749Phase 21 site📍 London London Health Sciences Centre Research Institute OR Lawson … · Tests: Radiation, Trans-Oral Surgery (TOS) + Neck Dissection 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial NCT05674396Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Stereotactic body radiotherapy, Traditional Palliation A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) NCT05894083Phase 21 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Surgery, Chemoradiation, Observation, Post-operative radiation A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer NCT05420948Phase 21 site📍 Chicago University of Chicago · Tests: Pembrolizumab, Carboplatin, Paclitaxel HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers NCT06487403NA1 site📍 Toronto University Health Network, Toronto · Tests: Standard of care external beam radiotherapy (single integrated boost), Standard of care external beam radiotherapy (two… A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07381075Phase 21 site📍 Chengdu West China Hospital · Tests: Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667Phase 224 sites📍 Changchun📍 Chengdu📍 Chengdu Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB500, Tislelizumab, Cisplatin, 5 - FU Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma NCT07586124Phase 215 sites📍 Beijing📍 Fuzhou📍 Guangzhou Lepu Biopharma Co., Ltd. · Tests: Becotatug Vedotin for Injection, Placebo, Pucotenlimab Injection The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR NCT05854823NA1 site📍 Zhuhai Fifth Affiliated Hospital, Sun Yat-Sen University · Tests: dose-reduced radiotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy